Innovacorp Partners with Dalhousie to Renew Infrastructure

The life sciences sector received another boost today, Oct. 28, when Premier Rodney MacDonald announced a major long-term investment in a new BioScience Enterprise Centre to be located at Dalhousie University. This new infrastructure will enable the sector to continue to thrive.

The province of Nova Scotia, through Innovacorp, will make a financial commitment of $1.6 million each year for 20 years to fund the initiative. The planned facility will replace the existing centre on Lower Water Street in Halifax, and relocate to Dalhousie University in spring 2011.

EastMed Inc. Receives FDA Clearance to Market Uresta™ in the U.S.

EastMed Inc., the medical manufacturing company that caters specifically to women's health and wellness, has received FDA clearance to market its flagship product, uresta™ Continence Care, in the U.S.

“We are delighted to get the official word from the FDA,” said James Lodigiani, president and CEO of EastMed. “Uresta ™ Continence Care offers an innovative and cost-effective option for the many women who suffer from SUI.”

ImmunoVaccine Technologies Named One of Canada's Top 10 Life Sciences Companies

ImmunoVaccine Technologies (IVT), a vaccine development company, has been selected as one of the winners of Canada's Top 10 Life Sciences Companies (WWW.TOPCANADIANCOMPANIES.CA).

Winners are chosen by an independent expert panel of Canadian and U.S. venture capitalists. This award gives IVT the opportunity to present at the 12th Annual Ottawa Venture and Technology Summit on October 8, 2008 (WWW.OTTAWAVTS.COM).

ImmunoVaccine Technologies Broadens Its Patent Protection to Japan

ImmunoVaccine Technologies Inc. (IVT), a vaccine development company, today announced receipt of patent approval from the Japanese Patent Office for its vaccine platform.

The specific patent, vaccines with enhanced immune response and methods for their preparation, claims broad exclusivity that an effective, long-term immune response to treat a disease can be produced using a vaccine comprising of an antigen, an adjuvant, vesicles known as liposomes, and a hydrophobic carrier.


Subscribe to Innovacorp RSS